MedPath

Any additional pain relief in Trigeminal neuralgia patients with use of local anesthetic injection along with carbamazepine tablets

Phase 4
Not yet recruiting
Conditions
Cluster headaches and other trigeminal autonomic cephalgias (TAC),
Registration Number
CTRI/2025/05/087552
Brief Summary

Trigeminal neuralgia is a chronic type of neuropathic pain characterized by paroxysmal electric shock like pain that affects the individuals quality of life to a great extent Carbamazepine being the first line of drug for trigeminal neuralgia is primarily prescribed to the patient But due to its vast number of side effects it Is not well tolerated by the patient as dose increases Since it Is an excruciating pain condition there is need to explore more treatment modalities helping in attaining better pain relief There are few studies regarding use of Peripheral Nerve Blocks and Trigger zone injections with local anaesthetics along with routine drug therapy in refractory cases of Trigeminal Neuralgia patients with good results Its efficacy has been established in acute exacerbations of Trigeminal Neuralgia Lignocaine is being widely used in dentistry in topical as well as injectable form to treat several acute and chronic pain conditions with minimal adverse effects Performing lignocaine nerve blocks is a routine in office procedure in dental clinics More over to the best of our knowledge till now no studies have evaluated the therapeutic effectiveness and synergistic effect of 2 percent Lignocaine nerve blocks in routine management of Trigeminal Neuralgia patients The aim of the present study is to bridge that gap in literature and to evaluate the efficacy of this multimodal treatment strategy in trigeminal neuralgia patients

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
All
Target Recruitment
44
Inclusion Criteria

Patients diagnosed with Classical and Idiopathic Neuralgia Newly diagnosed Trigeminal Neuralgia patients or with remission of 1 months or more Patient consent for participation in this study.

Exclusion Criteria

Secondary Trigeminal Neuralgia patients Patients on anti psychotics History of excessive alcohol intake Hepatic or renal insufficiency Known tolerance or allergy to study drug Pregnancy or Lactation Non compliant during screening period.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1.Numeric Pain Rating Scale (NPRS) assessment of pain0 1 2 3 weeks 1 month 3 months
Secondary Outcome Measures
NameTimeMethod
1 To evaluate mean dose of carbamazepine used in both the groups2 To evaluate number of responders with 50 percent relief in pain.

Trial Locations

Locations (1)

Post Graduate Institute of Dental Sciences Rohtak

🇮🇳

Rohtak, HARYANA, India

Post Graduate Institute of Dental Sciences Rohtak
🇮🇳Rohtak, HARYANA, India
Dr Jyoti Bhatt
Principal investigator
9416649651
jyotibhatt84@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.